Saúl Astray-Gómez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saúl Astray-Gómez has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alexandra Cortés-Arciniegas
Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
2 shared publications Santiago Almanzo
Department of Otorhinolaryngology, Hospital Universitario i Politecnic La Fe, Valencia, Spain
2 shared publications- Abel Guzmán Calvete
Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
1 shared publication Adrián Hernández Moya
Department of Anesthesiology and Intensive Care, Hospital Universitari i Politecnic La Fe, Valencia, Spain
1 shared publicationAgustín Alamar Velázquez
Department of Otorhinolaryngology, Hospital Universitari i Politècnic La Fe, Valencia, Spain
1 shared publicationAlexandra Cortés-Arciniegas
Department of Otorhinolaryngology, Hospital Universitario i Politecnic La Fe, Valencia, Spain
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Caleo in The Journal of International Advanced Otology
- Vol. 22 (5) , 1-9
The Current Role of Blue Laser in Otologic Surgery: A Narrative Review
Blue laser technology, specifically the 445-450 nm wavelength blue diode laser, represents an emerging innovation in otologic surgery with unique photoangiolytic and hemostatic properties. This narrative review discusses evidence from otologic studies directly addressing the 445-450 nm blue diode laser to evaluate the clinical applications, outcomes, and safety profile of blue laser systems in ear surgery. The technology hasbeen explored in stapedotomy procedures for otosclerosis, middle ear paraganglioma excision, and cholesteatoma surgery. Preliminary and still limited clinical data suggest audiological outcomes broadly comparable to traditional carbon dioxide laser systems, with a proposed advantage in hemostasis and thermal. Direct otologic evidence remains limited to a small number of case series and retrospective comparisons, with most publications emerging between 2018 and 2025. This review identifies blue laser technology as a promising adjunct to the otologic surgeon’s armamentarium, warranting larger randomized controlled trials to establish definitive clinical guidelines and long-term safety profiles.
- 21 September 2026
- Published by Caleo in The Journal of International Advanced Otology
- Vol. 22 (5) , 1-9
Open AccessThe Current Role of Blue Laser in Otologic Surgery: A Narrative Review
Blue laser technology, specifically the 445-450 nm wavelength blue diode laser, represents an emerging innovation in otologic surgery with unique photoangiolytic and hemostatic properties. This narrative review discusses evidence from otologic studies directly addressing the 445-450 nm blue diode laser to evaluate the clinical applications, outcomes, and safety profile of blue laser systems in ear surgery. The technology hasbeen explored in stapedotomy procedures for otosclerosis, middle ear paraganglioma excision, and cholesteatoma surgery. Preliminary and still limited clinical data suggest audiological outcomes broadly comparable to traditional carbon dioxide laser systems, with a proposed advantage in hemostasis and thermal. Direct otologic evidence remains limited to a small number of case series and retrospective comparisons, with most publications emerging between 2018 and 2025. This review identifies blue laser technology as a promising adjunct to the otologic surgeon’s armamentarium, warranting larger randomized controlled trials to establish definitive clinical guidelines and long-term safety profiles.
- 27 August 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (10) , 5251-5256
Velopharyngeal Incompetence After Unilateral Botulinum Toxin Injection to the Lateral Pterygoid Muscle for Temporomandibular Joint Disorder
- 27 August 2026
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 78 (10) , 5251-5256
Velopharyngeal Incompetence After Unilateral Botulinum Toxin Injection to the Lateral Pterygoid Muscle for Temporomandibular Joint Disorder
- 1 October 2025
- Published by AVES YAYINCILIK A.Ş. in B-ENT
- Vol. 21 (4) , 183-186
Solitary Fibrous Tumor of the Sinonasal Cavity: Case Report and Literature Review
Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms, most commonly arising in the pleura, but occasionally presenting in extrapleural sites such as the sinonasal tract. Sinonasal SFTs account for less than 6% of head and neck SFTs and often mimic more common nasal pathologies, making diagnosis challenging. The case of a 59-year-old woman with progressive left nasal obstruction, epistaxis, facial paresthesia, and anosmiais reported. Imaging revealed a hypervascular mass (44 Å~ 18 Å~ 43 mm) occupying the left nasal cavity and extending into the adjacent sinuses. Preoperative embolization of the feeding vessels was performed to reduce intraoperative bleeding risk. The tumor was completely resected via an endoscopic approach. Histopathological examination confirmed an SFT with clear margins. Immunohistochemistry showed cluster of differentiation 34(CD34) and signal transducer and activator of transcription 6(STAT6) positivity, along with a low Ki-67 index, indicating low metastatic potential. The postoperative course was uneventful, and the patient remains disease-free at follow-up. Due to their rarity and nonspecific clinical presentation, sinonasal SFTs require a high index of suspicion. Immunohistochemical analysis is essential for definitive diagnosis. Preoperative embolization can be a valuable adjunct in managing vascular lesions. Complete surgical excision is the treatment of choice, and long-term surveillance is recommended to detect potential recurrence. Cite this article as: Almanzo S, Torralba IT, Arciniegas AC, et al. Solitary fibrous tumor of the sinonasal cavity: case report and literature review. B-ENT. 2026;21(4):183-186.
- 1 October 2025
- Published by AVES YAYINCILIK A.Ş. in B-ENT
- Vol. 21 (4) , 183-186
Solitary Fibrous Tumor of the Sinonasal Cavity: Case Report and Literature Review
Solitary fibrous tumors (SFTs) are rare mesenchymal neoplasms, most commonly arising in the pleura, but occasionally presenting in extrapleural sites such as the sinonasal tract. Sinonasal SFTs account for less than 6% of head and neck SFTs and often mimic more common nasal pathologies, making diagnosis challenging. The case of a 59-year-old woman with progressive left nasal obstruction, epistaxis, facial paresthesia, and anosmiais reported. Imaging revealed a hypervascular mass (44 Å~ 18 Å~ 43 mm) occupying the left nasal cavity and extending into the adjacent sinuses. Preoperative embolization of the feeding vessels was performed to reduce intraoperative bleeding risk. The tumor was completely resected via an endoscopic approach. Histopathological examination confirmed an SFT with clear margins. Immunohistochemistry showed cluster of differentiation 34(CD34) and signal transducer and activator of transcription 6(STAT6) positivity, along with a low Ki-67 index, indicating low metastatic potential. The postoperative course was uneventful, and the patient remains disease-free at follow-up. Due to their rarity and nonspecific clinical presentation, sinonasal SFTs require a high index of suspicion. Immunohistochemical analysis is essential for definitive diagnosis. Preoperative embolization can be a valuable adjunct in managing vascular lesions. Complete surgical excision is the treatment of choice, and long-term surveillance is recommended to detect potential recurrence. Cite this article as: Almanzo S, Torralba IT, Arciniegas AC, et al. Solitary fibrous tumor of the sinonasal cavity: case report and literature review. B-ENT. 2026;21(4):183-186.
- 1 August 2025
- Published by Wolters Kluwer Health in Otology & Neurotology
Eslicarbazepine as a Treatment for Vestibular Paroxysmia: Preliminary Results
Objective: To assess the potential of eslicarbazepine as an effective and tolerable treatment for vestibular paroxysmia compared to standard drugs. Patients: A cohort of five patients fulfilling criteria of probable or definite vestibular paroxysmia were included in the study. Intervention: Patients were treated with eslicarbazepine in daily regime with an initial dose of 400 mg. Main Outcome Measure: Reduction in number of crises of vestibular paroxysmia per week was measured according to patients’ self-report, to evaluate clinical efficacy. Results: Mean treatment period was 10.6 months. Mean follow-up period was 21 months. Four of the five patients treated with eslicarbazepine achieved a total response with one of the five patients having a partial response with a mean reduction of 70% in the number of crises. The response to the withdrawal of the drug was highly variable in each patient. The most common adverse effects identified in the cohort were nausea, vomiting, and mild biochemical abnormalities. Two of the five patients experienced stochastic effects, which motivated drug removal. Conclusion: Eslicarbazepine shows good preliminary results achieving symptomatic relief in patients diagnosed with vestibular paroxysmia. Its enhanced safety profile with less adverse effects and drug interactions with respect to standard therapies could facilitate therapeutical adherence without detriment of its efficacy.
- 1 August 2025
- Published by Wolters Kluwer Health in Otology & Neurotology
Eslicarbazepine as a Treatment for Vestibular Paroxysmia: Preliminary Results
Objective: To assess the potential of eslicarbazepine as an effective and tolerable treatment for vestibular paroxysmia compared to standard drugs. Patients: A cohort of five patients fulfilling criteria of probable or definite vestibular paroxysmia were included in the study. Intervention: Patients were treated with eslicarbazepine in daily regime with an initial dose of 400 mg. Main Outcome Measure: Reduction in number of crises of vestibular paroxysmia per week was measured according to patients’ self-report, to evaluate clinical efficacy. Results: Mean treatment period was 10.6 months. Mean follow-up period was 21 months. Four of the five patients treated with eslicarbazepine achieved a total response with one of the five patients having a partial response with a mean reduction of 70% in the number of crises. The response to the withdrawal of the drug was highly variable in each patient. The most common adverse effects identified in the cohort were nausea, vomiting, and mild biochemical abnormalities. Two of the five patients experienced stochastic effects, which motivated drug removal. Conclusion: Eslicarbazepine shows good preliminary results achieving symptomatic relief in patients diagnosed with vestibular paroxysmia. Its enhanced safety profile with less adverse effects and drug interactions with respect to standard therapies could facilitate therapeutical adherence without detriment of its efficacy.
- 15 July 2025
- Published by Elsevier in Acta Otorrinolaringologica (English Edition)
- Vol. 76 (5) , 512268
Aberrant intratympanic internal carotid artery
- 15 July 2025
- Published by Elsevier in Acta Otorrinolaringologica (English Edition)
- Vol. 76 (5) , 512268
Aberrant intratympanic internal carotid artery
- 9 June 2025
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 77 (8) , 3103-3106
Congenital Desmoid Tumor of the Larynx: A Therapeutic Challenge
Desmoid tumors affecting vital structures can be life-threatening despite their non-malignant behavior. The lack of standardized treatment poses a therapeutic challenge, particularly regarding the sequelae in pediatric patients. A one-month-old male patient presented with respiratory distress and stridor. Endoscopic exploration and computed tomography revealed a laryngeal tumor, which was confirmed as a desmoid tumor via biopsy. Systemic chemotherapy in combination with imatinib was initiated, leading to stabilization of the tumor size. A surgical approach for desmoid tumors may be unsuitable for pediatric patients due to excessive morbidity. In such cases, targeted therapies like tyrosine kinase inhibitors can effectively control the disease.
- 9 June 2025
- Published by Springer Nature in Indian Journal of Otolaryngology and Head & Neck Surgery
- Vol. 77 (8) , 3103-3106
Congenital Desmoid Tumor of the Larynx: A Therapeutic Challenge
Desmoid tumors affecting vital structures can be life-threatening despite their non-malignant behavior. The lack of standardized treatment poses a therapeutic challenge, particularly regarding the sequelae in pediatric patients. A one-month-old male patient presented with respiratory distress and stridor. Endoscopic exploration and computed tomography revealed a laryngeal tumor, which was confirmed as a desmoid tumor via biopsy. Systemic chemotherapy in combination with imatinib was initiated, leading to stabilization of the tumor size. A surgical approach for desmoid tumors may be unsuitable for pediatric patients due to excessive morbidity. In such cases, targeted therapies like tyrosine kinase inhibitors can effectively control the disease.